Aligos Therapeutics, Inc.
ALGS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001799448
No open-market purchases or sales by Aligos Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.2M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Superinvestors holding ALGS, Q2 2026
1 superinvestor reports holding Aligos Therapeutics, Inc. on Form 13F, worth $439.9K in total. Weight is Aligos Therapeutics, Inc.'s share of each 13F portfolio; actions compare shares with Q1 2026.
| Superinvestor | % of portfolio | Shares | Value | vs. previous quarter |
|---|---|---|---|---|
| HHLR Advisors (Hillhouse)Zhang Lei | 0.1% | 76,247 | $439.9K | Unchanged |
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of ALGS each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q3 2024
1 superinvestor holding at quarter end
Converted for a 1-for-25 split- Reduced
- HHLR Advisors (Hillhouse) (−38.9%)
Q2 2024
1 superinvestor holding at quarter end
- Added
- HHLR Advisors (Hillhouse) (+63.8%)
Q4 2023
1 superinvestor holding at quarter end
- Reduced
- HHLR Advisors (Hillhouse) (−17.5%)
Q4 2022
1 superinvestor holding at quarter end
- Reduced
- HHLR Advisors (Hillhouse) (−2.3%)
Q3 2021
1 superinvestor holding at quarter end
- Added
- HHLR Advisors (Hillhouse) (+9.2%)